Andrew Armstrong
Professor of MedicineOverview
I am a clinical and translational investigator focused on precision therapies and biomarkers in advanced prostate and other GU cancers. I oversee a large research team of clinical and lab based investigators focused on improving patient outcomes, preventing metastatic disease, and understanding the biology of aggressive prostate cancer. Some key themes:
1. Predictors of sensitivity and clinical efficacy of therapies in advanced prostate cancer
2. Novel designs of clinical trials and pharmacodynamic/translational studies in prostate, kidney, bladder cancer
3. Pre-operative models for drug development of novel agents in human testing in prostate cancer
4. Novel therapies and drug development for prostate, renal, bladder, and testicular cancer
5. Design of rational combination therapies in men with metastatic hormone-refractory prostate cancer
6. Developing prognostic and predictive models for progression and survival in metastatic prostate cancer
7. Examining surrogate markers of mortality in metastatic prostate cancer
8. Clear cell and non-clear cell renal cell carcinoma: natural history, sensitivity to novel agents including mTOR and VEGF inhibition
Positions
Professor of Medicine in the School of Medicine
2018 School of Medicine
Professor in Pharmacology and Cancer Biology in the School of Medicine
2021 School of Medicine
Professor in Urology in the School of Medicine
2018 School of Medicine
Member of the Duke Cancer Institute in the School of Medicine
2006 School of Medicine
Education
B.S.E. 1996
1996 Duke University
M.D. 2000
2000 University of Virginia, School of Medicine
M.Sc. 2008
2008 Johns Hopkins University
Internship/Residency, GENERAL INTERNAL MEDICINE
2003 University of Pennsylvania, School of Medicine
Fellowship, DIVISION OF ONCOLOGY/HEMATOLOGY
2006 Johns Hopkins University, School of Medicine
Clinical Trials
Publications, Grants & Awards
DCI Centers, Cancer Types & Labs
Offices & Contact
Durham, NC
27710 Duke Box 103861
Durham, NC
27710